elasmogen ltd logo

Elasmogen Ltd

Next Generation Therapeutic Biologics Elasmogen Ltd, the Aberdeen-based biologics drug discovery company, developing soluble and stable biologics for site specific delivery, with its focus on auto inflammatory diseases as well as on oncology.

Elasmogen is a part of the University of Aberdeen, and holds all IPs linked with soloMER_ Biologics. soloMERs are fully humanized, clinical candidate with VNAR domains (the smallest binding site so far identified in nature), which are derived from shark.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.elasmogen.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Liberty Building Foresterhill Health Campus, AB25 2ZP
Aberdeen
United Kingdom
Email
Contact Number
+44 1224 438545

In May 2015, Elasmogen and Almac Discovery, entered into an agreement to co-develop Elasmogens ELN/11. Under the terms, both parties will share the development costs, while Almac shall be responsible for the commercialization.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/elasmogen-ltd” connections=”true” suffix=””]

soloMERsTM are humanised versions of stable antibody (9% of an antibody) proteins, that were first discovered in sharks. It is believed that soloMERs bind specifically to the cancer tissue and will penetrate inside the tumor before releasing their war-head of anti-cancer drugs, maximizing the damage to the tumor and minimizing the toxic effects to healthy tissues.